Testing effectiveness (Phase 2)Not Yet RecruitingNCT06516926
What this trial is testing
SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
Who this might be right for
HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
Jiangsu HengRui Medicine Co., Ltd. 240